跳至主要内容
临床试验/2024-516500-42-00
2024-516500-42-00已完成4 期

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects under fasting condition.

Sun Pharmaceutical Industries Limited1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年12月16日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
入组人数
36
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Arshad Khuroo

Scientific

Sun Pharmaceutical Industries Limited

研究点 (1)

Loading locations...

相似试验

已完成
4 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Upadacitinib Prolonged Release Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with RINVOQ 15 mg prolonged-release tablets (Upadacitinib), Marketing Authorization Holder: AbbVie Deutschland GmbH & Co. KG Knollstraße 67061 Ludwigshafen Germany, in healthy adult, human subjects under fed condition.Axial spondyloarthritisCrohn’s diseaseAtopic dermatitisPsoriatic arthritisRheumatoid arthritisUlcerative colitis
2024-512771-12-00Sun Pharmaceutical Industries Limited32
已完成
4 期
Randomized, Open-label, Single-Dose, Two-treatment, Two-period, Cross-over, Pivotal Bioequivalence Study Comparing Amoxicilin/Clavulanic acid powder for oral suspension 600 mg/42.9 mg/5 mL to Augemntin ES 600 mg/42.9 mg/5 mL powder for oral suspension in Healthy Adult Male and Female Volunteers under Fed Conditions.Not applicable (submitted trial is a bioequivalence study in healthy subjects).
2023-503233-22-00Tarchominskie Zaklady Farmaceutyczne Polfa S.A.56
已完成
不适用
Pharmacodynamic and pharmacokinetic study of PEG Neutrogen 6 mg subcutaneous injectio
CTRI/2015/12/006426Virchow Biotech Private Limited24
已完成
不适用
Pharmacodynamic and pharmacokinetic study of Neutrogen 5 mcg/kg subcutaneous injectio
CTRI/2015/12/006415Virchow Biotech Private Limited24
已完成
Unknown
Comparative pharmacokinetic study of two different formulations of Edoxaban under fasting conditions.
CTRI/2023/06/054295Zuventus Healthcare Limited40